Skip to content
sellModerate cluster of 2

Lewis T Williams sold $1.5M of PTGX

director at Protagonist Therapeutics, Inc. 18,000 shares at an average of $82.42, traded Feb 17, 2026, filed Feb 18, 2026.

Warning score
53
Value
$1.5M
18,000 shares
Holdings after
7,825
-70% from before
From 52-week low
+135%
low $35.09, close $82.46
From 52-week high
-14%
high $95.35, as of Feb 17, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $1.5M at market
    +25
  • Share of holdings sold
    Sold 70% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +19.1%, 3m +21.6%, 6m +86.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTGXOct 12, 2026 · close 144.88
Since filing Feb 18, 2026: +74.6%SPY +14.3% · excess +60.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-26-017176, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 17, 2026MOption exercise
Common Stock
+18,000$10.84$195k25,825Feb 18, 2026
Feb 17, 2026SOpen-market sale
Common Stock
-18,000$82.42$1.5M7,825Feb 18, 2026
Feb 17, 2026MOption exercise
Stock Option (right to buy)derivative
+18,000$0.00$06,000Feb 18, 2026

Related signals

Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
22Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$8.3M
58,629 shares
-50%
20Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$18M
125,000 shares
-22%
20Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$15M
100,000 shares
-17%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$1.1M
9,000 shares
-53%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$969k
9,000 shares
-53%
24Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$897k
9,000 shares
-53%
28Weak
PTGXsell 210b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$7.5M
75,000 shares
-13%
48Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$7.5M
75,000 shares
-13%
53Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Bryan Giraudo
director
$5.9M
59,130 shares
-93%
34Weak
PTGXsell
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$185k
1,750 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Lewis T Williams sold $1.5M of PTGX | InsiderTell